CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 552 products for "CDK". Showing the first 500.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Formula:C24H16N6OS2Purity:98%Color and Shape:SolidMolecular weight:468.55IV-361
CAS:IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1Formula:C23H32FN5O2SiColor and Shape:SolidMolecular weight:457.625CDK7-IN-2 hydrochloride hydrate
CAS:CDK7-IN-2 HCl hydrate is a potent, specific CDK7 enzyme inhibitor with significant anti-cancer effects.Formula:C26H42ClN7O4Color and Shape:SolidMolecular weight:552.12Roccellic Acid
CAS:Roccellic acid from R. montagnei lichen has antibacterial, anticancer properties; MIC 46.9 μg/ml; inhibits cancer cells by up to 87.9%.Formula:C17H32O4Color and Shape:SolidMolecular weight:300.43BSJ-04-132
Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.Color and Shape:SolidCDK2/4-IN-1
CDK2/4-IN-1 (compound B-4a) serves as both a CDK2/4 inhibitor and a microtubule polymerization inhibitor, making it useful in cancer research.Color and Shape:Odour SolidRibociclib-D6 hydrochloride
Ribociclib-D6 hydrochloride is a deuterated form of Ribociclib hydrochloride (T15730), which is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and has over 1000-fold lower activity against the cyclin B/CDK1 complex.LSN3106729 hydrochloride
CAS:LSN3106729 hydrochloride, an Abemaciclib metabolite, is a CDK-inhibiting antitumor PROTAC CDK4/6 degrader.Formula:C25H29ClF2N8OColor and Shape:SolidMolecular weight:531.00LL-K8-22
LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.Formula:C37H43N5OColor and Shape:SolidMolecular weight:573.77KB-0742 hydrochloride
KB-0742 hydrochloride is a potent, selective, and orally active CDK9 inhibitor, with an IC50 of 6 nM for CDK9/cyclin T1. It exhibits over 50 times selectivity towards CDK9/cyclin T1 compared to other CDK kinases. Additionally, KB-0742 hydrochloride demonstrates effective antitumor activity.Cimpuciclib
CAS:Cimpuciclib is a cyclin-dependent kinase(CDK) inhibitor and antineoplastic.Formula:C30H35FN8OColor and Shape:SolidMolecular weight:542.663CDK7-IN-1
CAS:CDK7-IN-1, analog of YKL-5-124, inhibits cdk7 with IC50 < 100 nM.Formula:C28H35N7O3Color and Shape:SolidMolecular weight:517.634Abemaciclib metabolite M18
CAS:Abemaciclib M18 (LSN3106729), a potent CDK inhibitor with antitumor action, used in a PROTAC to degrade CDK4/6.Formula:C25H28F2N8OPurity:98%Color and Shape:SolidMolecular weight:494.54HTH-01-091 TFA
HTH-01-091 TFA: Potent, selective MELK inhibitor (IC50=10.5 nM); also targets PIM1/2/3, RIPK2, DYRK3, smMLCK, CLK2; used in breast cancer research.Formula:C28H29Cl2F3N4O4Color and Shape:SolidMolecular weight:613.46CDK12/13-IN-2
CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.Formula:C24H22FN7O2Color and Shape:SolidMolecular weight:459.48CDK12-IN-4
CAS:CDK12-IN-4 is a pyrazolotriazine that inhibits CDK12 (IC50: 0.641 μM) with high ATP (2 mM) and spares CDK2/Cyclin E and CDK9/Cyclin T1 (IC50: >20 μM).Formula:C20H20F2N8OColor and Shape:SolidMolecular weight:426.432NecroIr2
NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.Formula:C46H30ClIrN6O2Color and Shape:SolidMolecular weight:926.44NecroIr1
NecroIr1, an iridium(III) complex, induces necroptosis in Cisplatin-resistant lung cells, targeting mitochondria and disrupting MMP.Formula:C40H29ClIrN5OColor and Shape:SolidMolecular weight:823.36Men 10376
CAS:Men 10376 is a selective antagonist of tachykinin NK-2 receptor. It has a Ki of 4.4 μM for rat small intestine NK-2 receptor.Formula:C57H68N12O10Purity:98%Color and Shape:SolidMolecular weight:1081.22YKL-5-124 TFA
CAS:YKL-5-124 TFA is a potent CDK7 inhibitor (IC50: 53.5 nM), more than 100x selective over CDK9/2, not active on CDK12/13, and disrupts the cell cycle.Formula:C30H34F3N7O5Color and Shape:SolidMolecular weight:629.63CDK6/9-IN-1
CAS:CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).Formula:C22H25ClN8OColor and Shape:SolidMolecular weight:452.95Cell Cycle Compound Library
A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);Color and Shape:Odour SolidRef: TM-L8100
1mgTo inquire10μL*10mM (DMSO)To inquire20μL*10mM (DMSO)To inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquire(1S,3R,5R)-PIM447 dihydrochloride
(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).Formula:C24H25Cl2F3N4OPurity:98%Color and Shape:SolidMolecular weight:513.38CDK5-IN-1
CAS:CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.Formula:C24H25FN6O3SColor and Shape:SolidMolecular weight:496.56CDK2-IN-43
CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.Formula:C19H27N7OColor and Shape:SolidMolecular weight:369.464PROTAC CDK9 degrader-8
PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].Formula:C44H52Cl2N10O7Purity:98%Color and Shape:SolidMolecular weight:903.85CDK1-IN-2
CAS:CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.Formula:C17H11ClN2OPurity:98.53%Color and Shape:SoildMolecular weight:294.73Ref: TM-T64373
1mg52.00€1mL*10mM (DMSO)98.00€5mg102.00€10mg166.00€25mg334.00€50mg537.00€100mg767.00€500mg1,558.00€XY028-133
CAS:XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.Formula:C53H67N11O7SPurity:97.11%Color and Shape:SolidMolecular weight:1002.23Ref: TM-T13361
1mg110.00€5mg268.00€10mg467.00€1mL*10mM (DMSO)517.00€25mg802.00€50mg1,414.00€100mg2,457.00€CDK-IN-12
CAS:CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1].Formula:C26H29FN6OSColor and Shape:SolidMolecular weight:492.61Cdk2/Cyclin Inhibitory Peptide II
CAS:Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, demonstrates dose-dependent cytotoxic effects on U2OS osteosarcoma cells [1].Formula:C110H200N48O25Color and Shape:SolidMolecular weight:2595.07SNX7
CAS:SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Formula:C15H14N2OPurity:99.96%Color and Shape:SolidMolecular weight:238.28CDK7-IN-5
CAS:CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).Formula:C34H45N9O2Color and Shape:SolidMolecular weight:611.795PROTAC CDK9 degrader-2
CAS:PROTAC CDK9 degrader-2, potent, selective, IC50 17 μM in MCF-7, wogonin-derived, targets CRBN.Formula:C39H36N6O10Purity:98%Color and Shape:SolidMolecular weight:748.74CDK4/6-IN-11
CAS:CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.Formula:C43H49N11O7Color and Shape:SolidMolecular weight:831.92Kinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Color and Shape:Odour SolidRef: TM-L1600
1mgTo inquire10μL*10mM (DMSO)To inquire20μL*10mM (DMSO)To inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquireFDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Color and Shape:LiquidRef: TM-L1610
1mgTo inquire10μL*10mM (DMSO)To inquire20μL*10mM (DMSO)To inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquireLO-3-63
LO-3-63 is a Ribociclib analogue featuring a truncated fumaramide group and acts as a CDK4/6 degrader with PROTAC properties. It degrades CDK4/6 in cells via a CUL4DCAF16-dependent pathway.Color and Shape:Odour SolidCDK9 ligand 3
CAS:CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.Formula:C18H18BrCl2N5O3Color and Shape:SolidMolecular weight:503.177JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Formula:C53H69N5O9Purity:98%Color and Shape:SolidMolecular weight:920.161CDK4/6-IN-23
CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.Formula:C32H34FN7O4Color and Shape:SolidMolecular weight:599.655[pSer2, pSer5, pSer7]-CTD TFA
Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.Formula:C98H138F3N21O39Purity:98%Color and Shape:SolidMolecular weight:2291.25CDK7-IN-6
CAS:CDK7-IN-6, a potent CDK7 inhibitor (IC50 ≤100 nM), from WO2019197549 A1, is >200x selective over CDK1/2/5, promising for cancer research.Formula:C26H34ClN9OColor and Shape:SolidMolecular weight:524.07CDK9 inhibitor HH1
CAS:CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.Formula:C13H15N3OSPurity:99.92%Color and Shape:SolidMolecular weight:261.34CDK2-IN-7
CAS:CDK2-IN-7 is a CDK2 inhibitor for treating cancer ( IC 50 < 50 nM).Formula:C24H30N6O4SColor and Shape:SolidMolecular weight:498.6CPS2
CAS:CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.Formula:C38H42N12O10S2Color and Shape:SolidMolecular weight:890.94CDK9-IN-25
CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.Formula:C15H16FN5Purity:98%Color and Shape:SolidMolecular weight:285.32YX0597
YX0597 is a potent and selective CDK9 PROTAC degrader that reduces RNA polymerase II S2 phosphorylation and MCL1 expression in GA0518 and AGS cells. It effectively inhibits the growth of GEAC cells (including radioresistant tumors) and suppresses tumor proliferation, metastasis, and cancer stem cells.Color and Shape:Odour SolidEGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Formula:C49H32N12O2S2Purity:98%Color and Shape:SolidMolecular weight:884.99CDK7-IN-7
CAS:CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).Formula:C20H20BrF3N6O2Color and Shape:SolidMolecular weight:513.319CDK2/PIM1-IN-1
CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.Color and Shape:Odour Solid
